Arcus Files Preliminary Prospectus for Underwritten Common Stock Offering
RCUS is trading near its 52-week low of $16.41 (14% above the low) on elevated volume (2.9× avg).
Summary
Arcus launched an underwritten common stock offering, filing a preliminary prospectus that names Jefferies, Leerink and TD Cowen and references a $23.75 last sale on October 20. Size and pricing are not yet set; proceeds go to the casdatifan program and general corporate purposes.
Key Events · Financing and Capital Events · RCUS
-
Underwritten Common Stock Offering Launched
Arcus is selling newly issued common stock through Jefferies, Leerink Partners and TD Cowen, with a 30-day option for the underwriters to buy additional shares. Share count and price are left blank in the preliminary prospectus.
-
Pricing Reference and Dilution Not Yet Fixed
The filing cites a $23.75 last reported sale price on October 20, 2026, versus today's $18.75. With 127,018,631 shares outstanding as of June 30, 2026, final dilution depends on the price and size set at launch.
-
Proceeds Directed to Casdatifan Program
Net proceeds are earmarked to fund R&D, including expansion and acceleration of the casdatifan clinical development program, plus working capital and operating expenses.
-
Lock-Ups and ATM Suspension
Company and officers/directors agreed to 60-day lock-ups, with a carve-out letting one director sell up to 132,106 shares. Sales under the February 25, 2026 Equity Distribution Agreement are barred for 30 days after this offering.
Analysis · RCUS · Life Sciences
Arcus is selling new common stock in an underwritten offering, and the preliminary prospectus references a $23.75 last sale on October 20 — above today's $18.75, meaning the deal is being marketed into a stock that has already given back ground. Because the share count and price are still blank, the size and dilution are not yet fixed; final pricing terms will determine how much capital is raised and how much existing holders are diluted. Proceeds are earmarked for expanding and accelerating the casdatifan program, the asset behind the ARC-20 data presented October 20 that drove the stock higher. The company pre-announced roughly $694.0 million in cash as of September 30, so this raise is about funding the casdatifan push rather than averting a cash crunch. Near term, the 60-day lock-ups and the 30-day ATM suspension keep additional supply off the market.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RCUS was trading at $18.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $16.41 to $31.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.